| Population 2014 |
46 million |
| | |
| | | | | | | |
| Estimates of TB burden * 2014 |
Number (thousands) |
Rate
(per 100 000 population) |
| Mortality (excludes HIV+TB) |
0.23 |
(0.23–0.24) |
0.5 |
(0.5–0.51) |
| Mortality (HIV+TB only) |
0.061 |
(0.036–0.093) |
0.13 |
(0.08–0.2) |
| Prevalence (includes HIV+TB) |
6.8 |
(2.9–12) |
15 |
(6.3–27) |
| Incidence (includes HIV+TB) |
5.5 |
(4.8–6.2) |
12 |
(10–13) |
| Incidence (HIV+TB only) |
0.31 |
(0.27–0.37) |
0.68 |
(0.58–0.79) |
| |
|
|
|
|
| Case detection, all forms (%) |
88 |
(77–100) |
|
|
| | |
| | | | | | | |
| Estimates of MDR-TB burden * 2014 |
|
New |
|
Retreatment |
| % of TB cases with MDR-TB |
0.22 |
(0.03–0.8) |
7.1 |
(3.3–13) |
MDR-TB cases among notified pulmonary
TB cases |
8 |
(1–28) |
16 |
(8–30) |
| | |
| | | | | | | |
| TB case notifications 2014 |
New ** |
Relapse |
| Pulmonary, bacteriologically confirmed |
2 843 |
|
0 |
| Pulmonary, clinically diagnosed |
673 |
|
0 |
| Extrapulmonary |
1 302 |
|
0 |
| |
|
|
|
| Total new and relapse |
4 818 |
|
|
| Previously treated, excluding relapses |
230 |
|
|
| Total cases notified |
5 048 |
|
|
| | |
| | | | | | | |
| Among 4 811 new and relapse cases: | | | | | | |
| 297 (6%) cases aged under 15 years; male:female ratio: 1.5 | | | | |
| | | | | | | |
| Reported cases of RR-/MDR-TB 2014 |
New |
Retreatment |
Total ** |
| Cases tested for RR-/MDR-TB |
1 492 (52%) |
110 (48%) |
1 623 |
| Laboratory-confirmed RR-/MDR-TB cases |
|
|
39 |
| Patients started on MDR-TB treatment *** |
|
|
|
| | |
| | | | | | | |
| TB/HIV 2014 |
Number |
(%) |
| TB patients with known HIV status |
3 191 |
(63) |
| HIV-positive TB patients |
233 |
(7) |
| HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) |
|
|
| HIV-positive TB patients on antiretroviral therapy (ART) |
|
|
| HIV-positive people screened for TB |
|
|
| HIV-positive people provided with IPT |
|
|
| | |
| | | | | | | |
| Treatment success rate and cohort size |
(%) |
Cohort |
| New and relapse cases registered in 2013 |
(75) |
5 290 |
| Previously treated cases, excluding relapse, registered in 2013 |
(67) |
298 |
| HIV-positive TB cases, all types, registered in 2013 |
(58) |
283 |
| RR-/MDR-TB cases started on second-line treatment in 2012 |
|
|
| XDR-TB cases started on second-line treatment in 2012 |
|
|
| | |
| | | | | | | |
| Laboratories 2014 |
|
| Is second-line drug susceptibility testing available? |
Yes, in country |
| | |
| | | | | | | |
| Financing TB control 2015 |
|
| National TB programme budget (US$ millions) |
|
| | |
| | | | | | | |
| * Ranges represent uncertainty intervals | | | | | |
| ** Includes cases with unknown previous TB treatment history | | | |
| *** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having | |
| RR-/MDR-TB | | | | | | | |
| | | | | | | |